Reply
Núria Tarrats, Anna Moles, Albert Morales, Carmen García‐Ruiz, José C. Fernández‐Checa, Montserrat Marí – 2 September 2011
Drug therapy: Telaprevir
Michael D. Leise, W. Ray Kim, Katherine M. Canterbury, John J. Poterucha – 2 September 2011
Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China
Yiling Li, Chao Xing, Jonathan C. Cohen, Helen H. Hobbs – 2 September 2011
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive
Jérôme Boursier, Victor de Ledinghen, Jean‐Pierre Zarski, Isabelle Fouchard‐Hubert, Yves Gallois, Frédéric Oberti, Paul Calès, multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies – 2 September 2011 – The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm (BA), which cross‐check FibroTest with the aspartate aminotransferase‐to‐platelet ratio index (APRI) or FibroScan, are very accurate but provide only a binary diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or BA for F4).
Glucocorticoids increase interleukin‐6–dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor
Anna Dittrich, Christina Khouri, Sara Dutton Sackett, Christian Ehlting, Oliver Böhmer, Ute Albrecht, Johannes G. Bode, Christian Trautwein, Fred Schaper – 2 September 2011 – Glucocorticoids are known to be potent regulators of inflammation and have been used pharmacologically against inflammatory, immune, and lymphoproliferative diseases for more than 50 years. Due to their possible and well‐documented side effects, it is crucial to understand the molecular mechanisms and targets of glucocorticoid action in detail.
Apoptosis: A barrier against cancer no more?
Florian Baumgartner, Andreas Villunger – 2 September 2011
Commentary on emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferon therapy
Seyed Mohamad Jazayeri, Seyed Moayed Alavian – 2 September 2011
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model
Diego M. Avella, Guangfu Li, Todd D. Schell, Dai Liu, Samuel Shao‐Min Zhang, Xi Lou, Arthur Berg, Eric T. Kimchi, Hephzibah Rani S. Tagaram, Qing Yang, Serene Shereef, Luis S. Garcia, Mark Kester, Harriet C. Isom, C. Bart Rountree, Kevin F. Staveley‐O'Carroll – 2 September 2011 – The high rate of mortality and frequent incidence of recurrence associated with hepatocellular carcinoma (HCC) reveal the need for new therapeutic approaches.
Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations
Natasha K. Martin, Peter Vickerman, Alec Miners, Graham R. Foster, Sharon J. Hutchinson, David J. Goldberg, Matthew Hickman – 2 September 2011 – Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon‐α + ribavirin) has been shown to be cost‐effective for patients with no reinfection risk. We examined the cost‐effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non‐IDUs or no treatment.
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany, David R. Nelson, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 2 September 2011